Annexon Biosciences set terms for its initial public offering on Monday, with plans to offer 10 million shares priced at $14 to $16 each…
The company has applied to list on Nasdaq, under the ticker “ANNX.”
JP Morgan, BofA Securities and Cowen are underwriting the deal.
Proceeds will be used to fund clinical trials, R&DS and for working capital and other general corporate purposes.
“We are a clinical-stage biopharmaceutical company developing a pipeline of…
Continue reading at MARKETWATCH.com
